Vitronectin expression in rheumatoid arthritic synovia - Inhibition of plasmin generation by vitronectin produced in vitro

British Journal of Rheumatology

Volumn 37, Issue 6, 1998, Pages 620-629

  Tomasini Johansson, B R ^a,c   Milbrink, J ^b   Pejler, G ^c  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

Arthritis; Fibrinolysis; Plasmin; Vitronectin

Indexed keywords

ANTIBODY; FIBRIN; GLYCOPROTEIN; MESSENGER RNA; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE RECEPTOR; VITRONECTIN;

ARTICLE; CELL ADHESION; CLINICAL ARTICLE; CONNECTIVE TISSUE; CONTROLLED STUDY; FIBRIN DEPOSITION; FIBRINOLYSIS; FROZEN SECTION; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOPRECIPITATION; IN SITU HYBRIDIZATION; IN VITRO STUDY; INFLAMMATORY CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID;

EID: 0031878387     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/37.6.620     Document Type: Article

References (40)

1. Zacharski LR, Wojtukiewicz MZ, Costantini V, Ornstein DL, Memoli VA. Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemostasis 1992;18:104-16.
2. Krane SM, Simon LS. Rheumatoid arthritis: clinical features and pathogenetic mechanisms. Med Clin North Am 1986;70:263-84.
3. Hamilton JA, Campbell IK, Wojta J, Cheung D. Plasminogen activators and their inhibitors in arthritic disease. Ann NY Acad Sci 1992;667:87-100.
4. Chmielewska J, Wiman B. Determination of tissue plasminogen activator and its 'fast' inhibitor in plasma. Clin Chem 1986;32:482-5.
5. Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemostasis Thromb 1988;9:87-115.
6. Simpson AJ, Booth NA, Moore NR, Bennett B. Distribution of plasminogen activator inhibitor (PAI-1) in tissues. J Clin Pathol 1991;44:139-43.
7. Declerck PJ, de Mol M, Alessi MC. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. J Biol Chem 1988;263:15454-61.
8. Mimuro J, Loskutoff DJ. Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. J Biol Chem 1989;264:936-9.
9. Salonen EM, Vaheri A, Pollanen J, Stephens R, Andreasen P, Mayer M et al. Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin. J Biol Chem 1989;264:6339-43.
10. Wiman B, Almquist A, Sigurdardottir O, Lindahl T. Plasminogen activator inhibitor 1 (PAI) is bound to vitronectin in plasma. FEBS Lett 1988;242:125-8.
11. 3 binding to vitronectin. Nature 1996;383:441-3.
12. Deng G, Curriden SA, Wan S, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated adhesion and release? J Cell Biol 1996;134:1563-71.
13. Hayman EG, Pierschbacher MD, Ohgren Y, Ruoslahti E. Serum spreading factor (vitronectin) is present at the cell surface and in tissues. Proc Natl Acad Sci USA 1983;80:4003-7.
14. Falk RJ, Podack E, Dalmasso A, Jenette JC. Localization of S-protein and its relationship to the membrane attack complex of complement in renal tissue. Am J Pathol 1987;127:182-90.
15. Dahlbäck K, Löfberg H, Dahlbäck B. Immunohistochemical demonstration of vitronectin in association with elastin and amyloid deposits in human kidney. Histochemistry 1987;87:511-7.
16. Sawa H, Sobel BE, Fuji S. Potentiation by hypercholesterolemia of the induction of aortic intramural synthesis of plasminogen activator inhibitor type 1 by endothelial injury. Circ Res 1993;73:671-80.
17. Tomasini-Johansson BR, Sundberg C, Lindmark G, Gailit JO, Rubin K. Vitronectin in colorectal adenocarcinoma - synthesis by stromal cells in culture. Exp Cell Res 1994;214:303-12.
18. Conlan MG, Tomasini BR, Schultz RL, Mosher DF. Plasma vitronectin polymorphism in normal subjects and patients with disseminated intravascular coagulation. Blood 1988;72:185-90.
19. Seiffert D, Keeton M, Eguchi Y, Sawdey M, Loskutoff DJ. Detection of vitronectin mRNA in tissues and cells of the mouse. Proc Natl Acad Sci USA 1991;88:9402-6.
20. Barnes DW, Reing J. Human spreading factor: synthesis and response by HepG2 hepatoma cells in culture. J Cell Physiol 1985;125:207-14.
21. Tomasini-Johansson BR, Ruoslahti E, Pierschbacher MD. A 30 kD sulfated extracellular matrix protein immunologically crossreactive with vitronectin. Matrix 1993;13:203-14.
22. Declerck PJ, Collen D. Measurement of plasminogen activator inhibitor 1 (PAI-1) in plasma with various monoclonal antibody-based enzyme-linked immunosorbent assays. Thromb Res 1990;10(suppl.):3-9.
23. Spiteri MA, Clarke SW, Poulter LW. Isolation of pheno- atypically and functionally distinct macrophage subpopulations from human bronchoalveolar lavage. Eur Respir J 1992;5:717-26.
24. Rubin K, Johansson S, Pettersson I, Ocklind C, Obrink B, Hook M. Attachment of rat hepatocytes to collagen and fibronectin; a study using antibodies directed against cell surface components. Biochem Biophys Res Commun 1979;91:86-94.
25. Ivarsson M, Sundberg C, Farrokhnia N, Pertoft H, Rubin K, Gerdin B. Recruitment of type I collagen producing cells from the microvasculature in vitro. Exp Cell Res 1996;229:336-49.
26. Deutsch DG, Mertz ET. Plasminogen: purification from human plasma by affinity chromatography. Science 1970;170:1095-6.
27. Mulherin D, Fitzgerald O, Bresnihan B. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum 1996;39:115-24.
28. Nikkari L, Haapasalmi K, Aho H, Torvinen A, Sheppard D, Larjava H et al. Localization of the alpha v subfamily of integrins and their putative ligands in synovial lining cell layer. J Rheumatol 1995;22:16-23.
29. Hogasen K, Mollnes TE, Harboe M, Gotze O, Hammer HB, Oppermann M. Terminal complement pathway activation and low lysis inhibitors in rheumatoid arthritis synovial fluid. J Rheumatol 1995;22:24-8.
30. Rosenblum G, Carson S. Quantitation and distribution of vitronectin in synovial fluid and tissue of patients with rheumatic disease. Clin Exp Rheumatol 1996;14:31-6.
31. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994;264:569-71.
32. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995:270:1500-2.
33. Seiffert D, Bordin GM, Loskutoff DJ. Evidence that extrahepatic cells express vitronectin mRNA at rates approaching those of hepatocytes. Histochem Cell Biol 1996;105:195-201.
34. Gladson CL, Wilcox JN, Sanders L, Gillespie GY, Cheresh DA. Cerebral microenvironment influences expression of the vitronectin gene in astrocytic tumors. J Cell Sci 1995;108:947-56.
35. Ciambrone G, McKeown-Longo PJ. Vitronectin regulates the synthesis and localization of urokinase-type plasminogen activator in HT-1080 cells. J Biol Chem 1992;267:13617-22.
36. Kost C, Benner K, Stockmann A, Linder D, Preissner K. Limited plasmin proteolysis of vitronectin. Characterization of the adhesion protein as morpho-regulatory and angiostatin-binding factor. Eur J Biochem 1996;236:682-8.
37. Moser TL, Enghild JJ, Pizzo SV, Stack MS. Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA-dependent adhesion of U937 cells. Biochem J 1995;307:867-73.
38. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994;269:32380-8.
39. Preissner KT. Specific binding of plasminogen to vitronectin. Evidence for a modulatory role of vitronectin on fibrin (ogen)-induced plasmin formation by tissue plasminogen activator. Biochem Biophys Res Commun 1990:168:966-71.
40. Poole AR, Alini M, Hollander AP. Cellular biology of cartilage degradation. In: Mechanisms and models in rheumatoid arthritis. Academic Press, 1995:163-204.